Retrospective analysis shows disparities in overall survival for single vs. multiple T3 factors in patients, indicating significant prognostic implications.
This study aims to identify prognostic factors in operated patients with non-small cell lung cancer staged as T3N0M0 according to the 8th edition of the Tumor, Node, Metastasis (TNM) staging system. Between January 2010 and June 2023, a total of 79 patients (67 males, 12 females; mean age: 62.9±8.7; range, 40 to 80 years) who underwent surgery for non-small cell lung cancer and were pathologically staged as T3N0M0 were retrospectively analyzed. The patients were divided into two groups: the first group included 56 patients with a single T3 factor, while the second group included 23 patients with multiple T3 factors. Survival analysis was performed. The five-year overall survival rate for the first group was 79.0%, with a mean overall survival of 107.76±8.44 months (95% confidence interval [CI]: 91.21-124.32), while the second group had a five-year overall survival rate of 48.9%, with a mean overall survival of 69.19±12.60 months (95% CI: 44.48-93.91). This difference was statistically significant (p=0.02). In the multivariate analysis, multiple T3 factors (p=0.003) and the presence of comorbidity (p=0.004) were found to be independent poor prognostic factors. Our study results suggest that having multiple T factors significantly and adversely affect survival of patients with surgically treated pT3 non-small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Tombul et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: